MEREO BIOPHARMA GROUP PLC (MREO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 5.68M USD | Liabilities, Current |
| Cash and equivalents | 30.12M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.68M | $30.12M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $6.18M | $36.22M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $4.30M | $40.99M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $6.02M | $48.70M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.56M | $56.13M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.50M | $62.48M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $13.85M | $69.80M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $14.21M | $80.52M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $15.47M | $87.43M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $11.00M | $48.66M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $9.49M | $57.42M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $24.38M | $68.18M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |